All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML
During the 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), the AML Hub spoke to Mohamad Mohty, Hôpital Saint-Antoine and Sorbonne University, Paris, FR. We asked, When should we use FLAMSA regimens for transplantation conditioning in AML?
FLAMSA-like regimens: When should we use these for transplantation conditioning in AML?
In this video, Mohty summarizes data on allogeneic transplantation presented at the EBMT virtual meeting, regarding the use of FLAMSA (fludarabine, cytarabine, and amsacrine) conditioning regimens for patients with primary refractory or relapsed AML. Mohty believes FLAMSA options are proving to be useful and effective, giving hope to patients waiting for treatment.
Reduced relapse incidence with FLAMSA-RIC compared to busulfan/fludarabine conditioning for patients with acute myeloid leukemia
BuFlu conditioning in comparison with FLAMSA-TBI conditioning show lower relapse incidence and superior leukemia-free...
Comparing FLAMSA-Bu and FluBu2 conditioning treatments in patients with R/R AML
Allogeneic hematopoietic stem cell transplant (allo-HSCT) is currently the only curative treatment for patients with relapsed/refractory (R/R) acute myeloid leukemia...
Subscribe to get the best content related to AML delivered to your inbox